Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Free Cash Flow (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Free Cash Flow for 14 consecutive years, with -$11.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 54.08% year-over-year to -$11.8 million, compared with a TTM value of -$75.4 million through Dec 2025, up 40.95%, and an annual FY2025 reading of -$75.4 million, up 40.95% over the prior year.
  • Free Cash Flow was -$11.8 million for Q4 2025 at Karyopharm Therapeutics, down from -$5.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $25.3 million in Q4 2021 and bottomed at -$59.3 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$27.6 million, with a median of -$26.3 million recorded in 2022.
  • The sharpest move saw Free Cash Flow surged 182.16% in 2021, then crashed 206.23% in 2022.
  • Year by year, Free Cash Flow stood at $25.3 million in 2021, then plummeted by 206.23% to -$26.8 million in 2022, then surged by 30.76% to -$18.6 million in 2023, then plummeted by 38.59% to -$25.8 million in 2024, then surged by 54.08% to -$11.8 million in 2025.
  • Business Quant data shows Free Cash Flow for KPTI at -$11.8 million in Q4 2025, -$5.9 million in Q3 2025, and -$18.7 million in Q2 2025.